Here Are the Medicare Part D Drugs Expected to Face 2025 Price Negotiations
Notable Analyst Calls This Week: Microsoft, Starbucks and GM Among Top Picks
Weekend Reading | Regenerative materials move towards becoming a billion-dollar giant
For a deeper understanding of how Rebirth Element has come to this day and the expected future growth.
Cantor Highly Bullish on Amgen Obesity Drug, Starts Coverage at Overweight
Regeneron Pharmaceuticals Announces Dupixent Approved In The U.S. As The First-Ever Biologic Medicine For Patients With COPD
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Biogen to End Sage Deal for Neuro Candidate
Roche, Biogen Kidney Disease Drug Hits Main Goal in Late-stage Study
Pfizer Withdraws Sickle Cell Drug Oxbryta Over Safety Concerns
FDA Approves Osimertinib For Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer After Chemoradiation Therapy; Recommended Dose Is 80mg Daily Until Disease Progression Or Unacceptable Toxicity
Amgen Stock Slides 5% as Analysts Weigh in on Drug Study Results
Analyst Expectations For Amgen's Future
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
A Closer Look at Regeneron Pharmaceuticals's Options Market Dynamics
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Baird Reiterates Underperform on Amgen, Maintains $215 Price Target
Amgen Analyst Ratings
Amgen Shares Are Trading Lower After Following Atopic Dermatitis Data, Which Some Analysts Noted Did Not Meet Expectations Amid Competition in the Market.
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen Stock Slips 3% Following Phase 3 Data for Rocatinlimab, Uplizna